Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.43 |
| ▸ | LPL | P06858 | 5/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106141 | 0.85 | LIPG (0.39) | CA1CA2CA9AAK1F11 | |
| SCHEMBL25439441 | 0.82 | AAK1 (0.47) | CA1CA2CA9AAK1F11 | |
| SCHEMBL31188697 | 0.81 | CYP1A2 (0.51) | CA1CA2CA9AAK1F11 | |
| SCHEMBL3399990 | 0.80 | UCHL1 (0.35) | CA1CA2CA9AAK1HIF1A | |
| SCHEMBL4816734 | 0.78 | SMN1; SMN2 (0.51) | CA1CA2CA9AAK1F11 | |
| SCHEMBL257880 | 0.77 | LIPG (0.49) | CA1CA2CA9AAK1F11 | |
| SCHEMBL5727852 | 0.75 | PPARA (0.53) | CA1CA2CA9AAK1F11 | |
| SCHEMBL28895528 | 0.75 | CA1 (0.44) | CA1CA2CA9AAK1F11 | |
| SCHEMBL14168092 | 0.74 | CA1 (0.52) | CA1CA2CA9AAK1F11 | |
| SCHEMBL21164676 | 0.74 | AAK1 (0.49) | CA1CA2CA9AAK1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964635-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-9206177-B2 | Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists | SANOFI (FR) | 2015-12-08 | — | — | US | disclosed |
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20140378483-A1 | FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof | SANOFI (FR) | 2014-12-25 | — | — | US | disclosed |
| WO-2014135495-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| US-7598251-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-7459454-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1606266-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20060084651-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| EP-1606266-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004084813-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | STK25, ABL1, STK35 | CA1 3834/4885CA2 1477/4885CA9 4617/4885 |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | CA1 1793/4885CA2 1617/4885CA9 2775/4885 |
| US-20140378483-A1 | FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof | FGFR1, FGFR2, FGF2 | CA1 4180/4885CA2 2576/4885CA9 3926/4885 |
| US-20060084651-A1 | Chemical compounds | STK25, MAP3K5, STK35 | CA1 1806/4885CA2 643/4885CA9 2205/4885 |
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | STK25, ABL1, STK35 | CA1 3834/4885CA2 1477/4885CA9 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.